Liquidia shares surged in after-hours trading Tuesday after the biotechnology company agreed to pay a net $380.7 million to settle all outstanding litigation with United Therapeutics, removing a major legal threat to its fast-growing YUTREPIA franchise while giving up the drug’s indication for pulmonary hypertension associated with interstitial lung disease.
The agreement resolves six pending lawsuits between the companies and allows Liquidia to continue selling YUTREPIA without interruption for pulmonary arterial hypertension, or PAH. Liquidia closed the regular session at $26.81, down 3.1%, before jumping roughly 50% after the announcement, reflecting how much uncertainty surrounding YUTREPIA’s commercial future had been embedded in the stock. United Therapeutics shares were little changed in after-hours trading.
The settlement comes less than two weeks after a federal court dealt Liquidia a significant defeat. On September 30, the U.S. District Court for the District of Delaware found that two claims of United Therapeutics’ U.S. Patent No. 11,826,327 were valid and infringed by Liquidia. The claims cover the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease, raising the possibility that YUTREPIA could face restrictions extending beyond that indication.
United Therapeutics had argued following the ruling that it was entitled to an order directing the FDA to withdraw YUTREPIA’s approval, potentially removing the product from the market until revised labeling could be approved without PH-ILD. The settlement eliminates that broader risk: Liquidia has agreed not to appeal the patent ruling, has submitted a supplement removing PH-ILD from YUTREPIA’s label and will no longer promote the drug for that population.
The Price of Removing the Legal Overhang
Liquidia will make a net $175 million payment to United Therapeutics within 30 business days. Another $145.4 million will be paid in two installments of $72.7 million, due by January 31 and April 30, 2027.
Liquidia will separately pay $60.3 million this month to parties holding interests in antitrust litigation involving Treprostinil Injection. Combined, those payments bring the net financial impact disclosed by the company to $380.7 million. Liquidia is also terminating its promotional agreement covering generic Treprostinil Injection and will no longer commercially support that product.
The cash cost is substantial, but Liquidia enters the settlement from a considerably stronger financial position than it had before YUTREPIA’s commercial launch. The company reported preliminary, unaudited third-quarter YUTREPIA net product sales of $222.7 million and cash and equivalents of $396.1 million as of September 30.
YUTREPIA sales have accelerated quickly. Second-quarter net product sales were $170.4 million, up 31% sequentially, after the drug launched in June 2025. Liquidia generated $74.7 million of second-quarter net income and $96.3 million of adjusted EBITDA, while cash increased by $61.4 million during the quarter.
Preliminary third-quarter YUTREPIA sales imply sequential growth of about 31% again from the second quarter. That commercial trajectory helps explain why investors were willing to look past the settlement payment: rather than facing continuing uncertainty over whether litigation could disrupt its principal growth asset, Liquidia now has a clearer path to continue building the PAH franchise.
PAH Business Survives, but PH-ILD Opportunity Is Lost
The settlement narrows YUTREPIA’s addressable market. The FDA originally approved the inhaled treprostinil powder in May 2025 for both PAH and PH-ILD, allowing Liquidia to compete with United Therapeutics across two pulmonary hypertension populations. The FDA approval followed years of regulatory and patent disputes surrounding the product.
Liquidia will now relinquish the PH-ILD indication covered by the disputed patent claims while retaining PAH, where YUTREPIA has already developed meaningful commercial momentum. That tradeoff changes the long-term opportunity but removes the more immediate possibility of a court order disrupting sales of the product altogether.
The agreement also closes litigation extending well beyond the Delaware patent dispute. The companies will dismiss cases involving another United Therapeutics patent, a Liquidia patent claim against United Therapeutics, allegations involving trade secrets and breach of contract, and the Treprostinil Injection antitrust litigation. The settlement includes mutual releases and does not constitute an admission of liability by either company.
Liquidia said it intends to continue investing in YUTREPIA as well as L606, its investigational sustained-release inhaled treprostinil therapy. Management said the company believes it can meet its settlement obligations while continuing to fund the business.
The sharp after-hours move suggests investors are assigning substantial value to certainty around YUTREPIA’s PAH franchise. Liquidia is giving up hundreds of millions of dollars and an approved indication, but it is also removing a collection of lawsuits that threatened a product generating more than $220 million of quarterly sales less than a year and a half after launch.
Attention now shifts from the courtroom back to commercial execution. Liquidia’s full third-quarter results will provide a clearer picture of YUTREPIA’s profitability and cash generation, while subsequent quarters will show whether growth can remain strong with the product focused exclusively on PAH. The pace of that franchise expansion — and how quickly Liquidia rebuilds cash after the settlement payments — will determine whether Tuesday’s removal of legal risk ultimately justifies the price the company agreed to pay.